Many companies are concerned about the high upfront-costs only to have people discontinue the drugs, negating the long-term benefits, said Ben Barner, clinical pharmacy leader at insurance brokerage Brown & Brown
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide in non-diabetic patients with obesity and prior cardiovascular events [4,5]
Chong RLK, Chan ASE, Chua CMS, Lai YF
The Group Insurance Commission, the state agency that provides benefits to public employees in Massachusetts, also plans to stop covering GLP-1 weight loss drugs
Ipamorelin binds the GHS-R1a receptor and triggers pulsatile growth hormone release through that pathway, without producing measurable elevations in cortisol, prolactin, or aldosterone in published preclinical and early human studies
[11] There is a widening of the muscular hiatal tunnel and circumferential laxity of the phrenoesophageal ligament, allowing a portion of the gastric cardia to herniate upward into the posterior mediastinum